A detailed history of Advisor Group Holdings, Inc. transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 10,519 shares of BCLI stock, worth $11,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,519
Previous 10,519 -0.0%
Holding current value
$11,360
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.28 - $0.66 $61 - $145
-220 Reduced 2.05%
10,519 $5,000
Q4 2023

Feb 12, 2024

SELL
$0.15 - $0.4 $635 - $1,695
-4,239 Reduced 28.3%
10,739 $2,000
Q3 2023

Nov 13, 2023

BUY
$0.2 - $2.08 $847 - $8,817
4,239 Added 39.47%
14,978 $2,000
Q2 2023

Aug 10, 2023

SELL
$2.0 - $3.2 $400 - $640
-200 Reduced 1.83%
10,739 $22,000
Q1 2023

May 12, 2023

SELL
$1.43 - $3.3 $143 - $330
-100 Reduced 0.91%
10,939 $36,000
Q4 2022

Feb 10, 2023

BUY
$1.37 - $4.42 $274 - $884
200 Added 1.85%
11,039 $18,000
Q1 2022

May 04, 2022

SELL
$2.92 - $4.19 $236 - $339
-81 Reduced 0.74%
10,839 $1.33 Million
Q2 2021

Aug 02, 2021

SELL
$3.01 - $4.01 $39,313 - $52,374
-13,061 Reduced 54.46%
10,920 $42,000
Q1 2021

May 13, 2021

BUY
$3.46 - $7.88 $7,681 - $17,493
2,220 Added 10.2%
23,981 $92,000
Q4 2020

Feb 10, 2021

SELL
$3.99 - $17.73 $137,028 - $608,901
-34,343 Reduced 61.21%
21,761 $99,000
Q3 2020

Nov 12, 2020

BUY
$11.19 - $16.92 $540,521 - $817,303
48,304 Added 619.28%
56,104 $948,000
Q2 2020

Aug 14, 2020

SELL
$4.42 - $12.66 $3,094 - $8,862
-700 Reduced 8.24%
7,800 $87,000
Q1 2020

May 18, 2020

BUY
$4.01 - $8.88 $34,085 - $75,480
8,500 New
8,500 $40,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $39.4M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.